Defining undertreatment and overtreatment in older adults with cancer: a scoping literature review
PURPOSE The terms undertreatment and overtreatment are often used to describe
inappropriate management of older adults with cancer. We conducted a comprehensive …
inappropriate management of older adults with cancer. We conducted a comprehensive …
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently …
J Davies, M Patel, C Gridelli, F de Marinis… - PLoS …, 2017 - journals.plos.org
Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis
and receive limited benefit from conventional treatments, especially in later lines of therapy …
and receive limited benefit from conventional treatments, especially in later lines of therapy …
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
JL Derks, RJ Van Suylen, E Thunnissen… - European …, 2017 - Eur Respiratory Soc
Pulmonary large cell neuroendocrine carcinoma (LCNEC) is rare. Chemotherapy for
metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell …
metastatic LCNEC ranges from small cell lung carcinoma (SCLC) regimens to nonsmall cell …
Real-world treatment and survival of patients with advanced non-small cell lung cancer: a German retrospective data analysis
F Hardtstock, D Myers, T Li, D Cizova, U Maywald… - BMC cancer, 2020 - Springer
Background The objective of this study was to describe the real-world treatment and overall
survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer …
survival (OS) of German patients with a diagnosis of advanced non-small cell lung cancer …
Validation of algorithms in studies based on routinely collected health data: general principles
V Ehrenstein, M Hellfritzsch, J Kahlert… - American Journal of …, 2024 - academic.oup.com
Clinicians, researchers, regulators, and other decision-makers increasingly rely on evidence
from real-world data (RWD), including data routinely accumulating in health and …
from real-world data (RWD), including data routinely accumulating in health and …
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology …
AP Abernethy, A Arunachalam, T Burke, C McKay… - PloS one, 2017 - journals.plos.org
Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …
contemporary first-line treatments prescribed in the era before the introduction of immune …
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
N Magios, F Bozorgmehr, AL Volckmar… - Therapeutic …, 2021 - journals.sagepub.com
Background: Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
(NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted …
Potential Life‐Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada
J Gotfrit, JJW Shin, R Mallick, DJ Stewart… - The …, 2020 - academic.oup.com
Background Canada has an established publicly funded health care system with a complex
drug approval and funding process. After proof of efficacy (POE; key publication/presentation …
drug approval and funding process. After proof of efficacy (POE; key publication/presentation …
[HTML][HTML] Treatment patterns and clinical outcomes among metastatic non–small-cell lung cancer patients treated in the community practice setting
E Nadler, JL Espirito, M Pavilack, M Boyd… - Clinical Lung Cancer, 2018 - Elsevier
Introduction Multiple therapeutic options now exist for metastatic non–small-cell lung cancer
(mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC …
(mNSCLC). In this study we evaluated treatment patterns and outcomes in mNSCLC …